To purchase hard copies of this book, please email:
orders@intechopen.com
By only printing on demand InTech ensures our carbon footprint is kept to a minimum.
The data below shows the environmental impact of printing one single book:
52.81 kg wood
2.84 g CO2
47.95 ml Water
Share this page
Neuroblastoma - Present and Future
Edited by Hiroyuki Shimada, ISBN 978-953-307-016-2, Hard cover, 366 pages, Publisher: InTech, Published: February 08, 2012 under CC BY 3.0 license, in subject Oncology
DOI: 10.5772/1251
Neuroblastoma, once called "enigmatic", due to "unpredictable" clinical behaviors, is composed of biologically diverse tumors. Molecular/genomic properties unique to the individual tumors closely link to the clinical outcomes of patients. Establishing risk stratification models after analyzing biologic characteristics of each case has made a great success in patient management. However, the trend of improving survival rates in neuroblastoma over the last 30 years has started to level off, and currently available treatment modalities have almost reached to their maximized intensity. Furthermore, aggressive treatment causes significant long-term morbidities to the survivors. We really need to make the next step to the level of personalized medicine with more precise understanding of neuroblastoma biology. This book includes useful data and insights from the world's experts in this field. I believe this book can make an excellent contribution to all the investigators working hard and fighting for the children stricken by this disease.
This book is indexed in:
Book contents
- Chapter 1Genetic Factors Influencing the Risk and Clinical Outcome of Neuroblastoma
- Chapter 2Recurrent Neuroblastoma
- Chapter 3The Cell Biology of Neuroblastoma
- Chapter 4Neuroblastoma: A Malignancy Due to Cell Differentiation Block
- Chapter 5Interplay Between Protein Kinase C Isoforms Alpha and Epsilon, Neurofibromin, and the Ras/MAPK Pathway in Neuroblastoma Differentiation
- Chapter 6Alternative TrkA Splicing and Neuroblastoma
- Chapter 7Sympathetic Neurotransmitters in Neuroblastoma – Between Physiology and Pathology
- Chapter 8Bioactive Sphingolipids in Neuroblastoma
- Chapter 9The NBPF Gene Family
- Chapter 10Retinoic-Acid-Induced Downregulation of the 67 KDa Laminin Receptor Correlates with Reduced Biological Aggressiveness of Human Neuroblastoma Cells
- Chapter 11The Different Faces of Angiogenesis in Neuroblastoma
- Chapter 12Application of Molecular Mimicry to Target GD2 Ganglioside
- Chapter 13MicroRNA Target Signatures in Advanced Stage Neuroblastoma
- Chapter 14Molecular Chaperones as Prognostic Markers of Neuroblastoma
- Chapter 15Small Molecule Drugs and Targeted Therapies for Neuroblastoma
- Chapter 16FOXO Transcription Factors as Potential Therapeutic Targets in Neuroblastoma
- Chapter 17Oncolytic Poliovirus Therapy in a Mouse Model of Neuroblastoma: Preclinical Data Analysis and Future Studies
